Actinic keratosis treatment sales will expand through 2036, with antimetabolite chemotherapy agents holding 43.6% of the treatment segment in 2026. The market is projected to grow from USD 7,043.6 million in 2026 to USD 13,221.8 million by 2036, creating an incremental opportunity of USD 6,178.2 million between 2026 and 2036.